NSAIDs and PGE2 Levels in Vitrectomy Patients
Summary
The purpose of this study is to assess vitreous concentrations of nonsteroidal antiinflammatory drugs (NSAIDs) and prostaglandin E2 in patients treated with NSAIDs before vitrectomy. A total of 0.5 to 1 mL undiluted vitreous was removed from the midvitreous cavity at the beginning of the surgery before infusion with balanced salt solution. Samples were immediately frozen and stored at -40°C until analysis. Samples were evaluated in a masked fashion. Vitreous concentrations of the study drugs were quantified using a reverse-phase liquid chromatography mass spectroscopy system. The minimum quantification limit for ketorolac, bromfenac, nepafenac, and amfenac was 0.8 ng/mL. Prostaglandin E2 concentrations were determined using a commercially available competitive enzyme immunoassay kit (R \& D Systems, Minneapolis, MN).
Timeline
- Start
- 2014-03
- Primary completion
- 2014-11
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bromfenac | Other / unclassified | 0.09 % | Topical |
| Subject | Indomethacin | Small molecule | 0.5 % | Topical |
| Subject | Ketorolac | Other / unclassified | 0.5 % | Topical |
| Subject | Nepafenac | Other / unclassified | 0.1 % | Topical |